Douglas J. Schwartzentruber

Immunology and Microbiology · Life Sciences

53h-index23.0kcitations93works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(43), Cancer Immunotherapy and Biomarkers(28), CAR-T cell therapy research(20), Virus-based gene therapy research(13), Immune Cell Function and Interaction(13)

Publications93 total

Interleukins And Cellular Therapies For Melanoma
2024
Cytokines (IL-2, IFN, GM-CSF, etc.) Melanoma
2020
Cytokines (IL-2, IFN GM-CSF etc) Melanoma
2018
Prognostic role of BRAF mutation in malignant cutaneous melanoma.
Journal of Clinical Oncology·2018· 3 cited
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Journal for ImmunoTherapy of Cancer·2014· 206 citedOpen Access
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
D-Scholarship@Pitt (University of Pittsburgh)·2014
Yttrium-90 Microsphere-selective Internal Radiation Therapy With Chemotherapy (Chemo-SIRT) for Colorectal Cancer Liver Metastases
American Journal of Clinical Oncology·2012· 39 cited
A Mosaic Activating Mutation in <i>AKT1</i> Associated with the Proteus Syndrome
New England Journal of Medicine·2011· 872 citedOpen Access
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
New England Journal of Medicine·2011· 879 cited
Immunotherapy of advanced melanoma by intratumoral injections of autologous, purified dendritic cells transduced with gene construct of interleukin-12, with dose-dependent expression under the control of an oral activator ligand.
Journal of Clinical Oncology·2011· 9 cited
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6 th -7 th 2010"
Journal of Translational Medicine·2011· 31 citedOpen Access
A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
Journal of Clinical Oncology·2009· 14 cited
A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
Journal of Clinical Oncology·2009· 50 cited
A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
Journal of Clinical Oncology·2009· 85 cited
Phase II trial of multiagent chemotherapy combined with Y-90 microsphere selective internal radiation therapy (chemo-SIRT) in patients with colorectal cancer liver metastases
Journal of Clinical Oncology·2008· 1 cited
Quality of life in patients with advanced melanoma receiving vaccine therapy alone (V) or vaccine with high-dose interleukin-2 (V-HIL2)
Journal of Clinical Oncology·2007
PET probe-guided surgery: applications and clinical protocol
World Journal of Surgical Oncology·2007· 65 citedOpen Access
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.
PubMed·2006· 71 cited
Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion.
PubMed·2006· 55 cited
Discovery of ovarian cancer tumor vascular markers using immuno-LCM and transcriptional profiling.
Cancer Research·2006· 1 cited
page 1 of 5Next →

Frequent Co-authors

Steven A. Rosenberg(31), Suzanne L. Topalian(29), Donald E. White(23), Claudia A. Seipp(16), James Chih‐Hsin Yang(15), Patrick Hwu(15), Richard M. Sherry(12), Nicholas P. Restifo(11), Seth M. Steinberg(11), Kathleen E. Morton(9), Sharon Mavroukakis(8), Francesco M. Marincola(8), James C. Yang(8), John R. Wunderlich(6), Mark E. Dudley(5), Linda Rogers-Freezer(5), Jan Einhorn(5), Jeffrey S. Weber(5), Leah Haworth(4), Michael T. Lotze(4)